Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1694511

	registered interest
	date	07/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Magnetic Resonance Imagers
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the announcement at page 34 of the Spring Budget 2024, HC 560, published on 6 March 2024, on upgrading more than 100 MRI scanners with AI, what the average time taken for patients to receive relevant test results is; and if she will make an estimate of the average time for such results to be received when the new scanners are in use.
	tabling member constituency	Ilford North
	tabling member printed	Wes Streeting
	uin	17633
	answer	answer is ministerial correction date of answer 14/05/2024 answer text <p>The Department does not hold data on the average time taken for patients to receive relevant Magnetic Resonance Imaging (MRI) test results. The Department is, therefore, unable to make an estimate of the average time for such results to be received when the new scanners are in use. <br> <br> The National Health Service expects that upgrading one MRI scanner with Artificial Intelligence (AI) acceleration software will lead to an average of 3.71 additional patients being scanned per day in addition to the current average of 24 scans a day.</p><p> </p><p>The table below provides the figures which estimate that upgrading 100 MRI scanners will mean 130,000 additional patients receive an MRI test each year.</p><p> </p><table><tbody><tr><td><p><strong>Additional tests</strong> <strong>per upgraded scanner (hourly)</strong></p></td><td><p><strong>Additional tests per upgraded scanner </strong> <strong>(daily)</strong></p></td><td><p><strong>Additional tests</strong> <strong>per upgraded scanner </strong> <strong>(weekly)</strong></p></td><td><p><strong>Additional tests per upgraded scanner </strong> <strong>(annual)</strong></p></td><td><p><strong>Scanners upgraded</strong></p></td><td><p><strong>Additional Activity (annual)</strong></p></td></tr><tr><td><p>0.31</p></td><td><p>3.71</p></td><td><p>26</p></td><td><p>1,300</p></td><td><p>100</p></td><td><p>130,000</p></td></tr></tbody></table><p> </p><p>MRI AI acceleration software enables scan acquisition time to be reduced, in turn enabling scans to be delivered in shorter time frames and therefore improving the time taken for patients to receive a test result from the point of referral. This is currently supporting the achievement of optimal levels of throughput to be achieved in 80 trusts, where 216 scanners have been upgraded.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 17634 question first answered 14/05/2024 17:21:07 answering member 4044 label Biography information for Andrew Stephenson previous answer version 23781 answering member constituency Pendle answering member printed Andrew Stephenson answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4504 label Biography information for Wes Streeting

1694512

	registered interest
	date	07/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Magnetic Resonance Imagers
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to paragraph 2.20 of Spring Budget 2024, HC 560, if she will publish the modelling used to estimate the number of patients that will be impacted by the proposed upgrading of 100 MRI scanners.
	tabling member constituency	Ilford North
	tabling member printed	Wes Streeting
	uin	17634
	answer	answer is ministerial correction date of answer 14/05/2024 answer text <p>The Department does not hold data on the average time taken for patients to receive relevant Magnetic Resonance Imaging (MRI) test results. The Department is, therefore, unable to make an estimate of the average time for such results to be received when the new scanners are in use. <br> <br> The National Health Service expects that upgrading one MRI scanner with Artificial Intelligence (AI) acceleration software will lead to an average of 3.71 additional patients being scanned per day in addition to the current average of 24 scans a day.</p><p> </p><p>The table below provides the figures which estimate that upgrading 100 MRI scanners will mean 130,000 additional patients receive an MRI test each year.</p><p> </p><table><tbody><tr><td><p><strong>Additional tests</strong> <strong>per upgraded scanner (hourly)</strong></p></td><td><p><strong>Additional tests per upgraded scanner </strong> <strong>(daily)</strong></p></td><td><p><strong>Additional tests</strong> <strong>per upgraded scanner </strong> <strong>(weekly)</strong></p></td><td><p><strong>Additional tests per upgraded scanner </strong> <strong>(annual)</strong></p></td><td><p><strong>Scanners upgraded</strong></p></td><td><p><strong>Additional Activity (annual)</strong></p></td></tr><tr><td><p>0.31</p></td><td><p>3.71</p></td><td><p>26</p></td><td><p>1,300</p></td><td><p>100</p></td><td><p>130,000</p></td></tr></tbody></table><p> </p><p>MRI AI acceleration software enables scan acquisition time to be reduced, in turn enabling scans to be delivered in shorter time frames and therefore improving the time taken for patients to receive a test result from the point of referral. This is currently supporting the achievement of optimal levels of throughput to be achieved in 80 trusts, where 216 scanners have been upgraded.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 17633 question first answered 14/05/2024 17:21:07 answering member 4044 label Biography information for Andrew Stephenson previous answer version 23783 answering member constituency Pendle answering member printed Andrew Stephenson answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4504 label Biography information for Wes Streeting

1697083

	registered interest
	date	19/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Expenditure
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Answer of 12 October 2021 to Question 51702 on NHS: Expenditure, how much NHS England, clinical commissioning groups and integrated care boards spent in aggregate on (a) mental health services, (b) acute health services, (c) social care services, (d) primary medical services, (e) specialised services, (f) NHS continuing healthcare and (g) all other recorded spending categories in each financial year since 2015-16; and how much those organisations plan to spend in aggregate in each of those areas in the (i) 2023-24 and (ii) 2024-25 financial years.
	tabling member constituency	Ilford North
	tabling member printed	Wes Streeting
	uin	19413
	answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>The information requested up to 2023/24 is in the attached table due to its size. NHS England continues to work with integrated care boards (ICB) to develop their financial plans for 2024/25. Until that process is complete, we will not have a final agreed set of financial plans for the year ahead.</p><p>The £38 billion increase in clinical commissioning group and ICB direct commissioning spend between the 2019/20 and 2023/24 budgets reflects the record settlement for health and social care funding confirmed at the 2021 Spending Review.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 01/05/2024 16:20:23 answering member 4044 label Biography information for Andrew Stephenson attachment 1 file name FORMATTED TABLE FOR MINISTERIAL CLEARANCE PQ19413 table.docx title PQ19413 Table previous answer version 25896 answering member constituency Pendle answering member printed Andrew Stephenson answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4504 label Biography information for Wes Streeting

1698391

	registered interest
	date	25/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	United Lincolnshire Hospitals NHS Trust: Finance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how much funding her Department has provided to the United Lincolnshire Hospitals NHS Trust in each year since 2015.
	tabling member constituency	South Holland and The Deepings
	tabling member printed	Sir John Hayes
	uin	20153
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Department allocates resource funding to NHS England who then use that to fund a series of local budgets, managed by integrated care boards (ICBs) and national budgets, managed by NHS England themselves.</p><p>ICBs then use those agreed budgets to fund the purchase of healthcare services for their local population, mostly from NHS providers.</p><p>The Department does not hold a breakdown of the sources of income received by individual trusts, but for the years requested the United Lincolnshire Hospitals NHS Trust reported the following total income for its services in their year-end accounts:</p><table><tbody><tr><td><p>Financial Year</p></td><td><p>Operating income from patient care activities (£000)</p></td><td><p>Other operating income (£000)</p></td></tr><tr><td><p>2022/23</p></td><td><p>£708,886</p></td><td><p>£48,792</p></td></tr><tr><td><p>2021/22</p></td><td><p>£638,695</p></td><td><p>£41,499</p></td></tr><tr><td><p>2020/21</p></td><td><p>£531,696</p></td><td><p>£112,182</p></td></tr><tr><td><p>2019/20</p></td><td><p>£475,065</p></td><td><p>£64,183</p></td></tr><tr><td><p>2018/19</p></td><td><p>£413,754</p></td><td><p>£33,738</p></td></tr><tr><td><p>2017/18</p></td><td><p>£394,512</p></td><td><p>£38,649</p></td></tr><tr><td><p>2016/17</p></td><td><p>£392,427</p></td><td><p>£44,897</p></td></tr><tr><td><p>2015/16</p></td><td><p>£386,840</p></td><td><p>£36,588</p></td></tr><tr><td><p>2014/15</p></td><td><p>£395,007</p></td><td><p>£38,243</p></td></tr></tbody></table><p>Source: The United Lincolnshire Hospitals NHS Trust published annual report and accounts, 2014/15 to 2022/23.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 16:26:12 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	350 label Biography information for Sir John Hayes

1699201

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Attention Deficit Hyperactivity Disorder: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to tackle shortages of (a) methylphenidate and (b) other ADHD medications.
	tabling member constituency	Somerton and Frome
	tabling member printed	Sarah Dyke
	uin	20829
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>Disruptions to the supply of medicines used for the management of attention deficit hyperactivity disorder have been primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. The Department has been working hard with industry to help resolve those issues and expedite deliveries to boost supplies of these medicines, as quickly as possible. As a result of our ongoing activity and intensive work, some issues have been resolved. Many strengths of lisdexamphetamine, and all strengths of atomoxetine capsules, are now available. Medicine supply issues remain for some strengths of guanfacine, lisdexamphetamine, and methylphenidate. However, we continue to escalate these issues with the manufacturers to ensure that action is taken to resolve regulatory issues and expedite deliveries. We have been informed that these disruptions should largely be resolved by April or May 2024.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 17/04/2024 08:49:36 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4995 label Biography information for Sarah Dyke

1699968

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pharmacy: Finance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of medication costs on community pharmacies.
	tabling member constituency	Gosport
	tabling member printed	Dame Caroline Dinenage
	uin	20988
	answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>Through the medicine margin survey, the Department assesses whether the reimbursement arrangements pay pharmacy contractors as agreed as part of the community pharmacy contractual framework (CPCF). The medicine margin survey considers what pharmacies paid for medicines by looking at their invoices compared to the amount reimbursed by the National Health Service. Where the survey finds that they have been underpaid, we increase the pharmacy contractors’ payments, and where they have been overpaid, we decrease payments.</p><p>Furthermore, where pharmacies cannot purchase products at or below the Drug Tariff NHS reimbursement price, Community Pharmacy England can request that the Department reassesses the reimbursement price. If a new reimbursement price is issued, this is known as a concessionary price.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20979 question first answered 19/04/2024 09:54:36 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4008 label Biography information for Dame Caroline Dinenage

1699971

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she plans to develop a Priority Review programme for medical devices.
	tabling member constituency	Gosport
	tabling member printed	Dame Caroline Dinenage
	uin	20991
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Priority Review programme is not currently planned, but the Government is taking other significant steps for medical device regulatory reform, as part of a broader Medical Technology Strategy. Further information on the Medical Technology Strategy is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy" target="_blank">https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy</a></p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medical devices, and designates United Kingdom Approved Bodies to conduct conformity assessments against the relevant regulatory requirements. The MHRA works closely with Approved Bodies to ensure their timely assessment.</p><p> </p><p>Following a consultation on the future regulation of medical devices in 2021, the MHRA is leading a programme of work to introduce updated regulations for medical devices that prioritise patient safety, improve patient access to innovative medical devices, and ensure the UK remains an attractive market for medical technology innovators. In January of this year, the MHRA published a MedTech Regulatory roadmap that sets out the main activities in implementing the future regulations throughout 2024 and 2025. An international recognition framework for medical devices will form part of the future regulatory framework, which will provide an alternative route to the UK’s market, by leveraging approvals from comparable international regulators. The MHRA aims to publish an outline of the International Recognition Framework for medical devices later this spring, aligned to the Life Sciences Council, subject to necessary approvals.</p><p>In addition, the MHRA is leading the reform of the medical devices regulatory landscape and includes a new pathway to accelerate access to safe, innovative medical devices to help meet the unmet needs of patients. The Innovative Devices Access Pathway aims to bring new medical technologies and solutions to the National Health Service, to support the medical needs that are not currently being met. There are eight innovative medical technologies included in the pilot phase.</p><p>We are working alongside others to further the Life Sciences Vision, particularly improving regulation and regulatory processes around medical devices, and supporting broader ambitions in the vision aligned to the conditions set out in the Major Conditions Strategy. As we work to update the medical devices regulatory landscape, the MHRA is taking the Major Conditions Strategy into consideration, including the six groups of major health conditions.</p><p>The National Institute for Health and Care Excellence (NICE) is not a regulator but makes recommendations for the NHS on whether selected medical devices should be routinely adopted by the NHS, based on an assessment of their costs and benefits. Medical devices are prioritised for the NICE’s evaluation, in line with NICE’s published topic selection manual.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20992 20993 question first answered 22/04/2024 11:22:39 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4008 label Biography information for Dame Caroline Dinenage

1699972

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Equipment: Reviews
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Answer of 23 June 2023 to Question 189729 on Medicines and Healthcare products Regulatory Agency, whether she plans to initiate a priority review for medical devices.
	tabling member constituency	Gosport
	tabling member printed	Dame Caroline Dinenage
	uin	20992
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Priority Review programme is not currently planned, but the Government is taking other significant steps for medical device regulatory reform, as part of a broader Medical Technology Strategy. Further information on the Medical Technology Strategy is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy" target="_blank">https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy</a></p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medical devices, and designates United Kingdom Approved Bodies to conduct conformity assessments against the relevant regulatory requirements. The MHRA works closely with Approved Bodies to ensure their timely assessment.</p><p> </p><p>Following a consultation on the future regulation of medical devices in 2021, the MHRA is leading a programme of work to introduce updated regulations for medical devices that prioritise patient safety, improve patient access to innovative medical devices, and ensure the UK remains an attractive market for medical technology innovators. In January of this year, the MHRA published a MedTech Regulatory roadmap that sets out the main activities in implementing the future regulations throughout 2024 and 2025. An international recognition framework for medical devices will form part of the future regulatory framework, which will provide an alternative route to the UK’s market, by leveraging approvals from comparable international regulators. The MHRA aims to publish an outline of the International Recognition Framework for medical devices later this spring, aligned to the Life Sciences Council, subject to necessary approvals.</p><p>In addition, the MHRA is leading the reform of the medical devices regulatory landscape and includes a new pathway to accelerate access to safe, innovative medical devices to help meet the unmet needs of patients. The Innovative Devices Access Pathway aims to bring new medical technologies and solutions to the National Health Service, to support the medical needs that are not currently being met. There are eight innovative medical technologies included in the pilot phase.</p><p>We are working alongside others to further the Life Sciences Vision, particularly improving regulation and regulatory processes around medical devices, and supporting broader ambitions in the vision aligned to the conditions set out in the Major Conditions Strategy. As we work to update the medical devices regulatory landscape, the MHRA is taking the Major Conditions Strategy into consideration, including the six groups of major health conditions.</p><p>The National Institute for Health and Care Excellence (NICE) is not a regulator but makes recommendations for the NHS on whether selected medical devices should be routinely adopted by the NHS, based on an assessment of their costs and benefits. Medical devices are prioritised for the NICE’s evaluation, in line with NICE’s published topic selection manual.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20991 20993 question first answered 22/04/2024 11:22:39 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4008 label Biography information for Dame Caroline Dinenage

1699973

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether (a) the Medicines and Healthcare products Regulatory Agency and (b) NICE will prioritise the regulatory timelines for medical devices that (i) respond to conditions outlined in the Major Conditions Strategy and (ii) where there is unmet need.
	tabling member constituency	Gosport
	tabling member printed	Dame Caroline Dinenage
	uin	20993
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Priority Review programme is not currently planned, but the Government is taking other significant steps for medical device regulatory reform, as part of a broader Medical Technology Strategy. Further information on the Medical Technology Strategy is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy" target="_blank">https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy</a></p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medical devices, and designates United Kingdom Approved Bodies to conduct conformity assessments against the relevant regulatory requirements. The MHRA works closely with Approved Bodies to ensure their timely assessment.</p><p> </p><p>Following a consultation on the future regulation of medical devices in 2021, the MHRA is leading a programme of work to introduce updated regulations for medical devices that prioritise patient safety, improve patient access to innovative medical devices, and ensure the UK remains an attractive market for medical technology innovators. In January of this year, the MHRA published a MedTech Regulatory roadmap that sets out the main activities in implementing the future regulations throughout 2024 and 2025. An international recognition framework for medical devices will form part of the future regulatory framework, which will provide an alternative route to the UK’s market, by leveraging approvals from comparable international regulators. The MHRA aims to publish an outline of the International Recognition Framework for medical devices later this spring, aligned to the Life Sciences Council, subject to necessary approvals.</p><p>In addition, the MHRA is leading the reform of the medical devices regulatory landscape and includes a new pathway to accelerate access to safe, innovative medical devices to help meet the unmet needs of patients. The Innovative Devices Access Pathway aims to bring new medical technologies and solutions to the National Health Service, to support the medical needs that are not currently being met. There are eight innovative medical technologies included in the pilot phase.</p><p>We are working alongside others to further the Life Sciences Vision, particularly improving regulation and regulatory processes around medical devices, and supporting broader ambitions in the vision aligned to the conditions set out in the Major Conditions Strategy. As we work to update the medical devices regulatory landscape, the MHRA is taking the Major Conditions Strategy into consideration, including the six groups of major health conditions.</p><p>The National Institute for Health and Care Excellence (NICE) is not a regulator but makes recommendations for the NHS on whether selected medical devices should be routinely adopted by the NHS, based on an assessment of their costs and benefits. Medical devices are prioritised for the NICE’s evaluation, in line with NICE’s published topic selection manual.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20991 20992 question first answered 22/04/2024 11:22:40 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4008 label Biography information for Dame Caroline Dinenage

1699978

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of discontinuing funding for T1DE pilot schemes on the health and well-being of patients living with type 1 diabetes with disordered eating.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20895
	answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>NHS England has provided funding for eight integrated care boards (ICBs) across the country to support the development and establishment of Type 1 Diabetes with Disordered Eating (T1DE) services in every National Health Service region. Funding has been provided on a pump prime basis, and the responsibility for the longer-term sustainable provision of care for these patients sits with the relevant integrated care system.</p><p>A nationally commissioned evaluation has shown the positive impact that the provision of T1DE services can have for patients, including reductions in HbA1c, which is linked to reduced rates of diabetes complications, and reduced rates of emergency admissions.</p><p>It’s the role of the ICBs to consider the health needs of their populations, in making decisions about the care that is provided. It is expected that ICB leads consider these evaluation findings alongside the risk to patient health and wellbeing of the discontinuation of service provision, as well as other local contextual factors in making decisions about the future provision of T1DE services.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/04/2024 12:53:21 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth